Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. // Molecular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S152500162600715X?dgcid=rss_sd_all
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular Therapy. https://www.sciencedirect.com/science/article/pii/S152500162600715X?dgcid=rss_sd_all
“Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage.” Molecular Therapy.
@article{article59270,
title = {Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage},
journal = {Molecular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S152500162600715X?dgcid=rss_sd_all}
}